Structure Therapeutics: Small Molecule GLP-1 Opportunity

Goldman Sachs surging to fresh records as earnings top estimates, while some Mag7 stocks continue to struggle against the broader market. So will the big bank keep bumping, or can the big tech trouble make a turnaround? Plus the weight loss drug wars are heating up, with focus turning to the GLP-1 pill. The latest data from one pharma company, and what the CEO sees in store for the company as competition continues to climb.

Fast Money Disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.